Xian Deng
Stock Analyst at UBS
(4.52)
# 1,183
Out of 12,268 analysts
166
Total ratings
64%
Success rate
17.2%
Average return
Main Sectors:
Stocks Rated by Xian Deng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPA: IPN Ipsen S.A. | Maintained: Hold | $137 → $170 | $162.70 | +4.49% | 23 | May 19, 2026 | |
| ARGX argenx SE | Maintained: Hold | $850 | $806.46 | +5.40% | 33 | May 8, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Hold | n/a | $697.71 | - | 12 | May 8, 2026 | |
| ZLDPF Zealand Pharma A/S | Maintained: Buy | $760 → $730 | $50.26 | +1,352.45% | 3 | May 8, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Hold | $30 | $24.00 | +25.00% | 4 | Apr 1, 2026 | |
| LON: 0MGB Genmab A/S | Rated: Buy | $2,750 → $2,600 | $1,723.63 | +50.84% | 36 | Mar 26, 2026 | |
| LON: 0NZT UCB SA | Maintained: Buy | $300 → $330 | $242.15 | +36.28% | 22 | Feb 19, 2026 | |
| SWX: BIOV BioVersys AG | Initiated Coverage: Buy | $48 | $27.00 | +77.78% | 2 | Dec 11, 2025 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | $720 → $605 | $492.80 | n/a | 12 | Feb 6, 2023 | |
| FRA: MDG1 Medigene AG | Maintained: Buy | $8 | $0.0274 | n/a | 6 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $480 → $450 | $583.93 | n/a | 7 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $255 | $200.30 | n/a | 2 | Feb 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $31 | $20.28 | n/a | 4 | Nov 1, 2019 |
Ipsen S.A.
May 19, 2026
Maintained: Hold
Price Target: $137 → $170
Current: $162.70
Upside: +4.49%
argenx SE
May 8, 2026
Maintained: Hold
Price Target: $850
Current: $806.46
Upside: +5.40%
argenx SE
May 8, 2026
Maintained: Hold
Price Target: n/a
Current: $697.71
Upside: -
Zealand Pharma A/S
May 8, 2026
Maintained: Buy
Price Target: $760 → $730
Current: $50.26
Upside: +1,352.45%
Lakefront Biotherapeutics NV
Apr 1, 2026
Maintained: Hold
Price Target: $30
Current: $24.00
Upside: +25.00%
Genmab A/S
Mar 26, 2026
Rated: Buy
Price Target: $2,750 → $2,600
Current: $1,723.63
Upside: +50.84%
UCB SA
Feb 19, 2026
Maintained: Buy
Price Target: $300 → $330
Current: $242.15
Upside: +36.28%
BioVersys AG
Dec 11, 2025
Initiated Coverage: Buy
Price Target: $48
Current: $27.00
Upside: +77.78%
Lonza Group AG
Feb 6, 2023
Maintained: Buy
Price Target: $720 → $605
Current: $492.80
Upside: n/a
Medigene AG
Aug 4, 2022
Maintained: Buy
Price Target: $8
Current: $0.0274
Upside: n/a
May 26, 2020
Downgraded: Hold
Price Target: $480 → $450
Current: $583.93
Upside: n/a
Feb 17, 2020
Maintained: Buy
Price Target: $255
Current: $200.30
Upside: n/a
Nov 1, 2019
Maintained: Buy
Price Target: $31
Current: $20.28
Upside: n/a